Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery

Colloids and Surfaces B: Biointerfaces

Volumn 136, Issue , 2015, Pages 365-374

  Song, Huijuan ^a   Zhang, Ju ^b   Wang, Weiwei ^a   Huang, Pingsheng ^c   Zhang, Yumin ^d   Liu, Jianfeng ^d   Li, Chen ^a   Kong, Deling ^a,b  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^b NANKAI UNIVERSITY   (China)

^c TIANJIN UNIVERSITY   (China)

^d INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Cancer chemotherapy; Doxorubicin; PH sensitive; Prodrug nanoparticle

Indexed keywords

AMPHIPHILES; BINS; CELL CULTURE; CHEMOTHERAPY; DISEASES; MOLECULAR BIOLOGY; PEPTIDES; TUMORS;

CANCER CHEMOTHERAPY; DOXORUBICIN; DOXORUBICIN CONJUGATES; EFFICIENT DRUG DELIVERY; PH SENSITIVE; PRODRUGS; TARGETED DRUG DELIVERY; TUMOR-PENETRATING PEPTIDES;

NANOPARTICLES;

DOXORUBICIN; NANOPARTICLE; NEUROPILIN 1; NEUROPILIN 1 RECEPTOR; PRODRUG NANOPARTICLE; UNCLASSIFIED DRUG; ACID; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; ENDOCYTOSIS; FEMALE; HEART MUSCLE CELL; HYDROLYSIS; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; RECEPTOR BINDING; SLOW DRUG RELEASE; ADSORPTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HUMAN; INFRARED SPECTROSCOPY; KINETICS; NUDE MOUSE; PHYSIOLOGY; SCANNING ELECTRON MICROSCOPY; THERMODYNAMICS; TUMOR CELL LINE;

ACIDS; ADSORPTION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NEUROPILIN-1; POLYETHYLENE GLYCOLS; PRODRUGS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMODYNAMICS;

EID: 84943391063     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.09.030     Document Type: Article

References (60)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
2. Bildstein L., Dubernet C., Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv. Drug. Deliv. Rev. 2011, 63:3-23.
3. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Drug Discov. 2006, 6:688-701.
4. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., Savolainen J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7:255-270.
5. Luo C., Sun J., Sun B., He Z. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol. Sci. 2014, 35:556-566.
6. Du R., Xiao H., Guo G., Jiang B., Yan X., Li W., Yang X., Zhang Y., Li Y., Jing X. Nanoparticle delivery of photosensitive Pt(IV) drugs for circumventing cisplatin cellular pathway and on-demand drug release. Colloids Surf. B: Biointerfaces 2014, 123:734-741.
7. Li X.Q., Wen H.Y., Dong H.Q., Xue W.M., Pauletti G.M., Cai X.J., Xia W.J., Shi D., Li Y.Y. Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism. Chem. Commun. 2011, 47:8647-8649.
8. Wang Y., Wang H., Chen Y., Liu X., Jin Q., Ji J. pH and hydrogen peroxide dual responsive supramolecular prodrug system for controlled release of bioactive molecules. Colloids Surf. B: Biointerfaces 2014, 121:189-195.
9. Gou P., Liu W., Mao W., Tang J., Shen Y., Sui M. Self-assembling doxorubicin prodrug forming nanoparticles for cancer chemotherapy: synthesis and anticancer study in vitro and in vivo. J. Mater. Chem. B 2013, 1:284-292.
10. Zhu L., Wang T., Perche F., Taigind A., Torchilin V.P. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(17):47-17052.
11. Wang W., Li C., Zhang J., Dong A., Kong D. Tailor-made gemcitabine prodrug nanoparticles from well-defined drug-polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy. J. Mater. Chem. B 2014, 2:1891-1901.
12. Maiti S., Park N., Han J.H., Jeon H.M., Lee J.H., Bhuniya S., Kang C., Kim J.S. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug. J. Am. Chem. Soc. 2013, 135:4567-4572.
13. Yang Z., Lee J.H., Jeon H.M., Han J.H., Park N., He Y., Lee H., Hong K.S., Kang C., Kim J.S. Folate-based near-infrared fluorescent theranostic gemcitabine delivery. J. Am. Chem. Soc. 2013, 135(11):657-11662.
14. Cai T.T., Lei Q., Yang B., Jia H.Z., Cheng H., Liu L.H., Zeng X., Feng J., Zhuo R.X., Zhang X.Z. Utilization of H-bond interaction of nucleobase uralic with antitumor methotrexate to design drug carrier with ultrahigh loading efficiency and pH-responsive drug release. Regen. Biomater. 2014, 1:27-35.
15. Song H., Xiao H., Zhang Y., Cai H., Wang R., Zheng Y., Huang Y., Li Y., Xie Z., Liu T., Jing X. Multifunctional Pt(IV) pro-drug and its micellar platform: to kill two birds with one stone. J. Mater. Chem. B 2013, 1:762-772.
16. Zhang P., Cheetham A.G., Lin Y., Cui H. Self-assembled Tat nanofibers as effective drug carrier and transporter. ACS Nano 2013, 7:5965-5977.
17. Zhao Z., Meng H., Wang N., Donovan M.J., Fu T., You M., Chen Z., Zhang X., Tan W. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery. Angew. Chem. Int. Ed. 2013, 52:7487-7491.
18. Zhou Z., Ma X., Jin E., Tang J., Sui M., Shen Y., Van Kirk E.A., Murdoch W.J., Radosz M. Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. Biomaterials 2013, 34:5722-5735.
19. Lee C., Lo S.-T., Lim J., da Costa V.C.P., Ramezani S., Öz O.K., Pavan G.M., Annunziata O., Sun X., Simanek E.E. Design, synthesis and biological assessment of a triazinedendrimer with approximately 16 paclitaxel groups and 8 PEG groups. Mol. Pharm. 2013, 10:4452-4461.
20. Wu W., Driessen W., Jiang X. Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. J. Am. Chem. Soc. 2014, 136:3145-3155.
21. May J.P., Ernsting M.J., Undzys E., Li S.D. Thermosensitive liposomes for the delivery of gemcitabine and oxaliplatin to tumors. Mol. Pharm. 2013, 10:4499-4508.
22. Upadhyay K.K., Le Meins J.F., Misra A., Voisin P., Bouchaud V., Ibarboure E., Schatz C., Lecommandoux S. Biomimetic doxorubicin loaded polymersomes from hyaluronan-block-poly(gamma-benzyl glutamate) copolymers. Biomacromolecules 2009, 10:2802-2808.
23. Li M., Lv S., Tang Z., Song W., Yu H., Sun H., Liu H., Chen X. Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform. Macromol. Biosci. 2013, 13:1150-1162.
24. Pan L., Liu J., He Q., Shi J. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression. Adv. Mater. 2014, 26:6742-6748.
25. He Q., Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv. Mater. 2013, 26:391-411.
26. 2 for simultaneous tumor cell targeting and stimulus-induced drug release. Adv. Mater. 2013, 25:3485-3489.
27. Soepenberg O., de Jonge M.J.A., Sparreboom A., de Bruin P., Eskens F.A.L.M., de Heus G., Wanders J., Cheverton P., Ducharme M.P., Verweij J. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11:703-711.
28. Robinson D., Keating G. Albumin-bound paclitaxel. Drugs 2006, 66:941-948.
29. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Exp. Opin. Pharmcol. 2006, 7:1041-1053.
30. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
31. Pang X., Du H.L., Zhang H.Q., Zhai G.X., Zhai Y.J. Polymer-drug conjugates: present state of play and future perspectives. Drug Discov. Today 18 2013, 1316-1322.
32. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv. Drug. Deliv. Rev. 2009, 61:1131-1148.
33. Hamaguchi T., Doi T., Eguchi-Nakajima T., Kato K., Yamada Y., Shimada Y., Fuse N., Ohtsu A., Matsumoto S.I., Takanashi M., Matsumura Y. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 2010, 16:5058-5066.
34. Du C., Deng D., Shan L., Wan S., Cao J., Tian J., Achilefu S., Gu Y. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 2013, 34:3087-3097.
35. Liu R., Li Y., Zhang Z., Zhang X. Drug carriers based on highly protein-resistant materials for prolonged in vivo circulation time. Regen. Biomater. 2015, 2:125-133.
36. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., Pei Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
37. Oommen O.P., Garousi J., Sloff M., Varghese O.P. Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach. Macromol. Biosci. 2014, 14:327-333.
38. Mitra S., Gaur U., Ghosh P.C., Maitra A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 2001, 74:317-323.
39. Nam J.P., Park J.K., Son D.H., Kim T.H., Park S.J., Park S.C., Choi C., Jang M.K., Nah J.W. Evaluation of polyethylene glycol-conjugated novel polymeric anti-tumor drug for cancer therapy. Colloids Surf. B: Biointerfaces 2014, 120:168-175.
40. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., Ford J., Wu G., Kneller S., Davies J., Duncan R. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug. Chem. 2005, 16:775-784.
41. Duan X., Xiao J., Yin Q., Zhang Z., Yu H., Mao S., Li Y. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7:5858-5869.
42. She W., Li N., Luo K., Guo C., Wang G., Geng Y., Gu Z. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013, 34:2252-2264.
43. Li H., Bian S., Huang Y., Liang J., Fan Y., Zhang X. High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting. J. Biomed. Mater. Res. A 2014, 102:150-159.
44. Jiang T., Li Y.M., Lv Y., Cheng Y.J., He F., Zhuo R.X. Amphiphilic polycarbonate conjugates of doxorubicin with pH-sensitive hydrazone linker for controlled release. Colloids Surf. B: Biointerfaces 2013, 111:542-544.
45. Hu F.Q., Liu L.N., Du Y.Z., Yuan H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 2009, 30:6955-6963.
46. Yoo H.S., Lee E.A., Park T.G. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control. Release 2002, 82:17-27.
47. Sun D., Ding J., Xiao C., Chen J., Zhuang X., Chen X. Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin. ACS Appl. Mater. Interfaces 2014, 6:21202-21214.
48. Wei T., Liu J., Ma H., Cheng Q., Huang Y., Zhao J., Huo S., Xue X., Liang Z., Liang X. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 2013, 13:2528-2534.
49. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., Song Q., Yao L., Pang Z., Jiang X., Chen J., Chen H. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
50. Huang P., Liu J., Wang W., Li C., Zhou J., Wang X., Deng L., Kong D., Liu J., Dong A. Zwitterionic nanoparticles constructed with well-defined reduction-responsive shell and pH-sensitive core for spatiotemporally pinpointed drug delivery. ACS Appl. Mater. Interfaces 2014, 6(14):631-14643.
51. Song H., He R., Wang K., Ruan J., Bao C., Li N., Ji J., Cui D. Anti-HIF-1α antibody-conjugated pluronic triblock copolymers encapsulated with paclitaxel for tumor targeting therapy. Biomaterials 2010, 31:2302-2312.
52. Wang W., Zhang J., Li C., Huang P., Gao S., Han S., Dong A., Kong D. Facile access to cytocompatible multicompartment micelles with adjustable Janus-cores from A-block-B-graft-C terpolymers prepared by combination of ROP and ATRP. Colloids Surf. B: Biointerfaces 2014, 115:302-309.
53. Wang W., Song H., Zhang J., Li P., Li C., Wang C., Kong D., Zhao Q. An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform. J. Control. Release 2015, 203:57-66.
54. Xu P., Van Kirk E.A., Zhan Y., Murdoch W.J., Radosz M., Shen Y. Targeted charge-reversal nanoparticles for nuclear drug delivery. Angew. Chem. Int. Ed. 2007, 46:4999-5002.
55. Zhou Z., Shen Y., Tang J., Fan M., Van Kirk E.A., Murdoch W.J., Radosz M. Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Adv. Funct. Mater. 2009, 19:3580-3589.
56. Zhou Z., Shen Y., Tang J., Jin E., Ma X., Sun Q., Zhang B., Van Kirk E.A., Murdoch W.J. Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-targeted drug delivery. J. Mater. Chem. 2011, 21(19):114-19123.
57. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
58. Talelli M., Iman M., Varkouhi A.K., Rijcken C.J.F., Schiffelers R.M., Etrych T., Ulbrich K., van Nostrum C.F., Lammers T., Storm G., Hennink W.E. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 2010, 31:7797-7804.
59. Aryal S., Hu C.M., Zhang L. Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2009, 4:251-258.
60. She W., Luo K., Zhang C., Wang G., Geng Y., Li L., He B., Gu Z. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. Biomaterials 2013, 34:1613-1623.